A Phase 3 Study of ALXN2060 in Japanese Participants with Symptomatic ATTR-CM

Study identifier:ALXN2060-TAC-302

ClinicalTrials.gov identifier:NCT04622046

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 3, Prospective, Multicenter, Open Label, 2-Part Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ALXN2060 in Japanese Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Medical condition

Symptomatic Transthyretin Amyloid Cardiomyopathy

Phase

Phase 3

Healthy volunteers

No

Study drug

ALXN2060

Sex

All

Actual Enrollment

25

Study type

Interventional

Age

n/a - n/a

Date

Study Start Date: 13 Nov 2020
Primary Completion Date: 08 Nov 2023
Estimated Study Completion Date: 23 Sept 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2024 by Alexion Pharmaceuticals, Inc.

Sponsors

Alexion Pharmaceuticals, Inc.

Collaborators

Eidos Therapeutics

Inclusion and exclusion criteria